Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway

Highlights • Sirt1 activation ameliorated cutaneous inflammation and fibrosis in bleomycin induced scleroderma mice. • mTOR activation is associated with the pathogenesis of SSc. • Inhibition of mTOR pathway activation might be the mechanism of Sirt1 ameliorating SSc.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatological science 2017-08, Vol.87 (2), p.149-158
Hauptverfasser:	Zhu, Xiaoxia, Chu, Haiyan, Jiang, Shuai, Liu, Qingmei, Liu, Lei, Xue, Yu, Zheng, Shucong, Wan, Weiguo, Qiu, Jianhua, Wang, Jiucun, Zou, Hejian
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biopsy Bleomycin - toxicity Cells, Cultured Collagen - metabolism Cytokines - metabolism Dermatology Disease Models, Animal Enzyme-Linked Immunosorbent Assay Female Fibroblast Fibroblasts Gene Knockdown Techniques Humans Immunohistochemistry Inflammation Mice Mice, Inbred C3H Phosphorylation Real-Time Polymerase Chain Reaction RNA, Messenger Scleroderma, Systemic - blood Scleroderma, Systemic - chemically induced Scleroderma, Systemic - pathology Signal Transduction Sirolimus - pharmacology Sirtuin 1 - metabolism Skin - pathology Stilbenes - pharmacology Systemic sclerosis TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - genetics TOR Serine-Threonine Kinases - metabolism Tumor Necrosis Factor-alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Sirt1 activation ameliorated cutaneous inflammation and fibrosis in bleomycin induced scleroderma mice. • mTOR activation is associated with the pathogenesis of SSc. • Inhibition of mTOR pathway activation might be the mechanism of Sirt1 ameliorating SSc.
ISSN:	0923-1811 1873-569X
DOI:	10.1016/j.jdermsci.2017.04.013